FK506 and the role of the immunophilin FKBP-52 in nerve regeneration

Drug Metabolism Reviews

Volumn 31, Issue 3, 1999, Pages 649-663

  Gold, Bruce G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ESTRADIOL; ESTROGEN RECEPTOR; FK 506 BINDING PROTEIN; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; MOLYBDIC ACID; MONOCLONAL ANTIBODY; STEROID HORMONE; TACROLIMUS;

ANIMAL MODEL; CONFERENCE PAPER; DRUG MECHANISM; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; MOUSE; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROTROPISM; NONHUMAN; ONCOGENE C JUN; PERIPHERAL NERVE INJURY; PROTEIN EXPRESSION; SCIATIC NERVE;

ANIMALS; ANTIBODIES; BENZOQUINONES; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; LACTAMS, MACROCYCLIC; MICE; MICE, KNOCKOUT; MOLYBDENUM; NERVE REGENERATION; NEURITES; QUINONES; STEROIDS; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 0032776433     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101940     Document Type: Conference Paper

References (75)

1. B. G. Gold, FK506 and the role of immunophilins in nerve regeneration, Mol. Neurobiol., 15, 285-306 (1997).
2. T. Kino, H. Hatanaka, M. Hashimoto, and H. Nishiyama, FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physio-chemical and biological characteristics, J. Antibiot., 40, 1249-1255 (1987).
3. T. Kino, H. Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and T. Ochiai, FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J. Antibiot., 40, 1256-1265 (1987).
4. A. L. Hoffman, L. Makowka, B. Banner, X. Cai, D. V. Cramer, A. Pascualone, S. Todo, and T. E. Starzl, The use of FK-506 for small intestine allotransplantation: Inhibition of acute rejection and prevention of fatal graft-versus-host disease, Transplantation, 49, 483-490 (1990).
5. T. E. Starzl, L. Makowka, and S. Todo, FK-506: A potential breakthrough in immunosuppression, Transplant. Proc., 19, S3-S104 (1987).
6. T. E. Starzl, S. Todo, J. Fung, A. J. Demetris, R. Venkataramman, and A. Jain, FK-506 for liver, kidney, and pancreas transplantation, Lancet, 2, 1000-1004 (1989).
7. T. Kino and T. Goto, Discovery of FK-506 and update, Ann. NY Acad. Sci. 685, 13-21 (1993).
8. S. V. McDiarmid, R. W. Busuttil, N. L. Ascher, A. J. Burdick, A. M. D'Alessandro, C. Esquivel, M. Kalayoglu, A. S. Klein, J. W. Marsh, C. M. Miller, M. E. Schwartz, B. W. Shaw, and S. K. So, FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation, Transplantation, 59, 530-536 (1995).
9. R. Shapiro, J. J. Fung, A. B. Jain, P. Parks, S. Todo, and T. E. Starzl, The side effects of FK506 in humans, Transplant. Proc., 22, 35-36 (1990).
10. S. L. Schreiber and G. R. Crabtree, The mechanism of action of cyclosporin A and FK506, Immunol. Today, 13, 136-142 (1992).
11. S. L. Schreiber, Chemistry and biology of the immunophilins and their immunosuppressive ligands, Science, 251, 283-287 (1991).
12. E. S. Alnemri, T. Fernandes-Alnemri, D. S. Nelki, K. Dudley, G. C. DuBois, and G. Litwack, Overexpression, characterization, and purification of a recombinant mouse immunophilin FKBP-52 and identification of an associated phosphoprotein, Proc. Natl. Acad. Sci. USA, 90, 6839-6843 (1993).
13. N. H. Sigal and F. J. Dumont, Cyclosporin A, FK-506, and Rapamycin: Pharmacologic probes of lymphocyte signal transduction, Annu. Rev. Immunol., 10, 519-560 (1992).
14. D. A. Freman, C. B. Klee, B. E. Bierer, and S. J. Burakoff, Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A, Proc. Natl. Acad. Sci. USA, 89, 3686-3690 (1992).
15. P. J. Dyck, A. C. Lais, J. L. Karnes, M. Sparks, H. Hunter, and P. A. Low, Permanent axotomy, a model of axonal atrophy and secondary segmental demyelination and remyelination, Ann. Neurol., 19, 575-583 (1981).
16. J. Liu, J. D. Farmer, W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes, Cell, 66, 807-815 (1991).
17. C. T. Walsh, L. D. Zydowsky, and F. D. McKeon, Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction, J. Biol. Chem., 267, 13,115-13,118 (1992).
18. N. Terada, R. Or, K. Weinberg, J. Domenico, J. J. Lucas, and E. W. Gelfand, Transcription of IL-4 genes is not inhibited by cyclosporin A in competent T cells, J. Biol. Chem., 267, 21,207-21,210 (1992).
19. M. J. Tocci, D. A. Matkovich, K. Matkovich, K. A. Collier, P. Kwok, F. Dumont, S. Lin, S. Degudicibus, J. J. Siekerka, J. Chin, and N. I. Hutchinson, The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes, J. Immunol., 143, 718-726 (1989).
20. J. P. Steiner, T. M. Dawson, M. Fotuhi, C. E. Glatt, A. M. M. Snowman, N. Cohen, and S. H. Snyder, High brain densities of the immunophilin FKBP colocalized with Calcineurin, Nature, 358, 584-587 (1992).
21. W. E. Lyons, J. P. Steiner, S. H. Snyder, and T. M. Dawson, Neuronal regeneration enhances the expression of the immunophilin FKBP-12, J. Neurosci., 15, 2985-2994 (1995).
22. E. R. Sánchez and Y.-M. Ning, Immunophilins, heat shock protein, and glucocorticoid receptor actions in vivo, Methods Enzymol., 9, 188-200 (1996).
23. S. H. Snyder and D. M. Sabatini, Immunophilins and the nervous system, Nature Med., 1, 32-37 (1995).
24. G. Wiederrecht and F. Etzkorn, The immunophilins, Perspect. Drug Discov. Des., 2, 57-84 (1994).
25. M. W. Harding, A. Galat, D. E. Uehling, and S. L. Schreiber, A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase, Nature, 341, 758-760 (1989).
26. J. J. Siekierka, S. H. Y. Hung, M. Poe, C. S. Lin, and N. H. Sigal, A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin, Nature, 341, 755-757 (1989).
27. J. J. Siekierka, G. Wiederrecht, H. Greulich, D. Boulton, S. H. Y. Hung, J. Cryan, P. J. Hodges, and N. H. Sigal, The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase, J. Biol. Chem., 265, 21,011-21,015 (1990).
28. W. E. Lyons, J. P. Steiner, T. M. Dawson, and S. H. Snyder, Increased expression of FK-506 binding protein during peripheral nerve regeneration, Soc. Neurosci. Abstr., 18, 604 (1992).
29. C. B. Klee, Concerted regulation of protein phosphorylation and dephosphorylation by calmodulin, Neurochem. Res., 16, 1059-1065 (1991).
30. B. G. Gold, T. Storm-Dickerson, D. R. Austin, and K. Katoh, FK506, an immunosuppressant, increases functional recovery and axonal regeneration in the rat following axotomy of the sciatic nerve. Soc. Neurosci. Abstr., 19, 1316 (1993).
31. B. G. Gold, T. Storm-Dickerson, and D. R. Austin, The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury, Restor. Neurol. Neurosci., 6, 287-296 (1994).
32. B. G. Gold, K. Katoh, and T. Storm-Dickerson, The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve, J. Neurosci., 15, 7505-7509 (1995).
33. M. S. Wang, M. Zeleny-Pooley, and B. G. Gold, Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in rat sciatic nerve, J. Pharmacol. Exp. Ther., 282, 1084-1093 (1997).
34. A. Carreau, J. Gueugnon, J. Benavides, and X. Vigé, Comparative effects of FK-506, rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons, Neuropharmacology, 36, 1755-1762 (1997).
35. J. P. Steiner, M. A. Connolly, H. L. Valentine, G. S. Hamilton, T. M. Dawson, L. Hester, and S. H. Snyder, Neurotrophic actions of nonimmunosuppressive ligands of immunophilins, Nature Med., 3, 1-8 (1997).
36. J. P. Steiner, G. S. Hamilton, D. T. Ross, H. L. Valentine, H. Guo, M. A. Connolly, S. Liang, C. Ramsey, J. Li, W. Huang, P. Howorth, R. Soni, M. Fuller, H. Sauer, A. C. Nowotnik, and P. D. Suzdak, Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models, Proc. Natl. Acad. Sci. USA, 94, 2019-2024 (1997).
37. B. G. Gold, M. Zeleny-Pooley, M.-S. Wang, P. Chaturvedi, and D. M. Armistead, A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration, Exp. Neurol., 147, 269-278 (1997).
38. A. M. Cameron, F. C. Nucifora, Jr., E. T. Fung, D. J. Livingston, R. A. Aldape, C. A. Ross, and S. H. Snyder, FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain, J. Biol. Chem., 272, 27,582-27,588 (1997).
39. W. Shou, B. Agihdasi, D. L. Armstron, Q. Guo, S. Bao, M.-J. Charng, L. M. Mathews, M. D. Schneider, S. L. Hamilton, and M. M. Matsuk, Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12, Nature, 391, 489-492 (1998).
40. B. G. Gold, V. Densmore, W. Shou, M. M. Matzuk, and H. S. Gordon, Immunophilin FK506 binding protein 52 (not FK506 binding protein 12) mediates the neurotrophic action of FK506. J. Pharmacol. Exp. Therap., 289, 1202-1210 (1999).
41. K. J. Jones, Gonadal steroids as promoting factors in axonal regeneration, Brain Res. Bull., 30, 491-498 (1993).
42. W. B. Pratt and D. O. Toft, Steroid receptor interactions with heat shock protein and immunophilin chaperones, Endocr. Rev., 18, 306-360 (1997).
43. W. B. Pratt, The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors, Proc. Soc. Exp. Biol. Med., 217, 420-434 (1998).
44. T. Scheibel, T. Weikl, and J. Buchner, Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence, Proc. Natl. Acad. Sci. USA, 95, 1495-1499 (1998).
45. 1 cells, J. Biol. Chem., 260, 14,009-14,015 (1985).
46. B. G. Gold, J. Y. Yew, and M. Zeleny-Pooley, The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons, Neuroscience, 241, 25-28 (1998).
47. L. I. Benowitz, and A. Routtenberg, GAP-43: An intrinsic determinant of neuronal development and plasticity, Trends Neurosci., 20, 84-91 (1997).
48. G. L. Yao and H. Kiyama, Dexamethasone enhances level of GAP-43 mRNA after nerve injury and facilitates re-projection of the hypoglossal nerve, Mol. Brain Res., 32, 308-312 (1995).
49. K. J. Jones, S. M. Drengler, and M. M. Oblinger, Gonadal steroid regulation of growth-associated protein GAP-43 mRNA expression in axotomized hamster facial motor neurons, Neurochem. Res., 22, 1367-1374 (1997).
50. B. J. L. Eggen, H. B. Nielander, M. G. A. Rensen-de Leeuw, S. P. Chotman, W. H. Gispen, and L. H. Schrama, Identification of two promoter regions in the rat B-50/GAP-43 gene, Mol. Brain Res., 23, 221-234 (1994).
51. T. Herdegen, P. Skene, and M. Bohr, The c-jun transcription factor - bipotential mediator of neuronal death, survival and regeneration, Trends Neurosci., 20, 227-231 (1997).
52. C. Yardin, F. Terro, M. Lesort, F. Esclaire, and J. Hugon, FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures, NeuroReport, 9, 2077-2080 (1998).
53. T. M. Dawson, J. P. Steiner, V. L. Dawson, J. L. Dinerman, G. R. Uhl, and S. H. Snyder, Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity, Proc. Natl. Acad. Sci. USA, 90, 9808-9812 (1993).
54. J. Sharkey and S. P. Butcher, Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia, Nature, 371, 336-339 (1994).
55. T. Ide, E. Morikawa, and T. Kirino, An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the Mongolian gerbil, Neurosci. Lett., 204, 157-160 (1996).
56. T. Tokime, K. Nozaki, and H. Kikuchi, Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil, Neurosci. Lett., 206, 81-84 (1996).
57. Y. Yagita, K. Kitagawa, K. Matsushita, A. Taguchi, T. Mabuchi, T. Ohtsuki, T. Yanagihara, and M. Matsumoto, Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils, Life Sci., 59, 1643-1650 (1996).
58. J. Sharkey, J. H. Crawford, S. P. Butcher, and H. M. Marston, Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats, Stroke, 27, 2282-2286 (1996).
59. S. Kuroda and B. K. Siesjo, Postischemic administration of FK506 reduces infarct volume following transient focal brain ischemia, Neurosci. Res. Commun., 19, 83-90 (1996).
60. S. P. Butcher, D. C. Henshall, Y. Teramura, K. Iwasaki, and J. Sharkey, Neuroprotective actions of FK506 in experimental stroke: In vivo evidence against an antiexcitotoxic mechanism, J. Neurosci., 17, 6939-6946 (1997).
61. W. M. J. Obermann, H. Sondermann, A. A. Russo, N. P. Pavletich, and F. U. Hartl, In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis, J. Cell Biol., 143, 901-910 (1998).
62. P.-K. K. Tai, H. Chang, M. W. Albers, S. L. Schreiber, D. O. Toft, and L. E. Faber, P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors, Biochemistry, 32, 8842-8847 (1993).
63. Y. Miyata, B. Chambraud, C. Radanyi, J. Leclerc, M.-C. Lebeau, J.-M. Renoir, R. Shirai, M.-G. Catelli, I. Yahara, and E.-E. Baulieu, Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: Regulation of HSP90-binding activity of FKBP52, Proc. Natl. Acad. Sci. USA, 94, 14,500-14,505 (1997).
64. M. J. Czar, J. K. Owens-Grillo, A. W. Yem, K. L. Leach, M. R. Deibel, Jr., M. J. Welsh, and W. B. Pratt, The hsp56 immunophilin component of untransformed steroid receptor complexes is localized both to microtubules in the cytoplasm and to the same nonrandom regions within the nucleus as the steroid receptor, Mol. Endocrin., 8, 1731-1741 (1994).
65. J. F. Dillman III, L. P. Dabney, and K. K. Pfister, Cytoplasmic dynein is associated with slow axonal transport, Proc. Natl. Acad. Sci. USA, 93, 141-144 (1996).
66. R. A. Nixon, The slow axonal transport of cytoskeletal proteins, Curr. Opin. Cell Biol., 10, 87-92 (1998).
67. G. Sétáló, Jr., M. Singh, M. F. Warren, and D. Toran-Allerand, Direct association of heat shock protein HSP90 and the extracellular signal regulated kinases, ERK1/2. A possible link between estrogen and neurotrophin signaling, Soc. Neurosci. Abstr., 23, 1710 (1997).
68. C. Volonte, J. M. Angelastro, and L. A. Greene, Association of protein kinases ERK1 and ERK2 with p75 nerve growth factor receptors, J. Biol. Chem., 268, 21,410-21,415 (1993).
69. S. Cowley, H. Paterson, P. Kemp, and C. J. Marshall, Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells, Cell, 77, 841-852 (1994).
70. R. D. York, H. Yao, T. Dillon, C. L. Ellig, S. P. Eckert, E. W. McCleskey, and P. J. S. Stork, Rapl mediates sustained MAP kinase activation induced by nerve growth factor, Nature, 392, 622-626 (1998).
71. W. E. Lyons, E. B. George, T. M. Dawson, J. P. Steiner, and S. H. Snyder, Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia, Proc. Natl. Acad. Sci. USA, 91, 3191-3195 (1994).
72. K. D. Dittmar, D. R. Demady, L. F. Stancato, P. Krishna, and W. B. Pratt, Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery, J. Biol. Chem., 272, 21,213-21,220 (1997).
73. Q. Song, E. S. Alnemri, G. Litwack, and L. I. Gilbert, An immunophilin is a component of the insect ecdysone receptor (EcR) complex, Insect Biochem. Mol. Biol., 27, 973-982 (1997).
74. R. Kraft, R. B. Levine, and L. L. Restifo, The steroid hormone 20-hydroxyecdysone enhances neurite growth of Drosophila mushroom body neurons isolated during metamorphosis, J. Neurosci., 18, 8886-8899 (1998).
75. P. Vittorioso, R. Cowling, J.-D. Faure, M. Caboche, and C. Bellini, Mutation in the Arabidopsis PASTICCINO1 gene, which encodes a new FK506-binding protein-like protein, has a dramatic effect on plant development, Mol. Cell Biol., 18, 3034-3043 (1998).